Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Gut microbiome variation is associated to Multiple Sclerosis phenotypic subtypes

  • Reynders, Tatjana
  • Devolder, Lindsay
  • Vallès Colomer, Mireia
  • Van Remoortel, Ann
  • Joossens, Marie
  • De Keyser, Jacques
  • Nagels, Guy
  • D'hooghe, Marie Beatrice
  • Raes, Jeroen
Objective: Multiple sclerosis (MS) is a heterogenous, inflammatory disease of the central nervous system. Microbiota alterations in MS versus healthy controls (HC) are observed, but results are inconsistent. We studied diversity, enterotypes, and specific gut microbial taxa variation between MS and HC, and between MS subgroups. Methods: Amplicon sequencing of the 16S ribosomal RNA V4 region (Illumina MiSeq) was used to evaluate alpha and beta diversity, enterotypes, and relative taxa abundances on stool samples. MS subgroups were based on phenotype, disease course modifiers, and treatment status. Results were controlled for recently identified confounders of microbiota composition. Results: Ninety-eight MS patients and 120 HC were included. Microbial richness was lower in interferon-treated (RRMS_I, N = 24) and untreated relapsing-remitting MS during relapse (RRMS_R, N = 4) when compared to benign (BMS, N = 20; Z = -3.07, Pcorr = 0.032 and Z = -2.68, Pcorr = 0.055) and primary progressive MS (PPMS, N = 26; Z = -2.39, Pcorr = 0.062 and Z = -2.26, Pcorr = 0.071). HC (N = 120) and active untreated MS (RRMS_U, N = 24) showed intermediate microbial richness. Enterotypes were associated with clinical subgroups (N = 218, χ2 = 36.10, P = 0.002), with Bacteroides 2 enterotype being more prevalent in RRMS_I. Butyricicoccus abundance was lower in PPMS than in RRMS_U (Z = -3.00, Pcorr = 0.014) and BMS (Z = -2.56, Pcorr = 0.031), lower in RRMS_I than in BMS (Z = -2.50, Pcorr = 0.034) and RRMS_U (Z = -2.91, Pcorr = 0.013), and inversely correlated with self-reported physical symptoms (rho = -0.400, Pcorr = 0.001) and disease severity (rho = -0.223, P = 0.027). Interpretation: These results emphasize the importance of phenotypic subcategorization in MS-microbiome research, possibly explaining previous result heterogeneity, while showing the potential for specific microbiome-based biomarkers for disease activity and severity., MJ is funded by a postdoctoral fellowship from Research Foundation—Flanders. The Raes lab is supported by the VIB, the Rega institute for Medical Research, KU Leuven, the FWO EOS program (30770923), FP7 METACARDIS (305312), H2020 SYSCID (733100), PIBD-SET (668023), and IMMUNAID (779295). This work was funded by an FWO research grant (G038318N) to MD and JR. Financial support for this project in the MS center was provided in 2015, 2016 and 2017, commissioned by the Belgian National MS society with the support of the Fund D.V., managed by the King Baudouin Foundation (2016-C5812060-206012).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Open science resources for the discovery and analysis of Tara Oceans data

  • Pesant, Stéphane
  • Acinas, Silvia G.
  • Tara Oceans Consortium
Pesant, Stéphane ... et. al.-- 16 pages, 5 figures, 2 tables.-- This article is contribution number 26 of the Tara Oceans Consortium, The Tara Oceans expedition (2009–2013) sampled contrasting ecosystems of the world oceans, collecting environmental data and plankton, from viruses to metazoans, for later analysis using modern sequencing and state-of-the-art imaging technologies. It surveyed 210 ecosystems in 20 biogeographic provinces, collecting over 35,000 samples of seawater and plankton. The interpretation of such an extensive collection of samples in their ecological context requires means to explore, assess and access raw and validated data sets. To address this challenge, the Tara Oceans Consortium offers open science resources, including the use of open access archives for nucleotides (ENA) and for environmental, biogeochemical, taxonomic and morphological data (PANGAEA), and the development of on line discovery tools and collaborative annotation tools for sequences and images. Here, we present an overview of Tara Oceans Data, and we provide detailed registries (data sets) of all campaigns (from port-to-port), stations and sampling events, We thank the commitment of the following people and sponsors who made this singular expedition possible: CNRS (in particular the Groupement de Recherche GDR3280), European Molecular Biology Laboratory (EMBL), Genoscope/CEA, Fund for Scientific Research—Flanders, VIB, Stazione Zoologica Anton Dohrn, UNIMIB, ANR (projects POSEIDON/ANR-09-BLAN-0348, BIOMARKS/ANR-08-BDVA- 003, PROMETHEUS/ANR-09-GENM-031, PROMETHEUS/ANR-09-PCS-GENM-217, TARAGIRUS/ANR-09-PCS-GENM-218, OCEANOMICS/ANR-11-BTBR-0008, FRANCE GENOMIQUE/ANR-10-INBS-09-08), EU FP7 (MicroB3/No.287589, IHMS/HEALTH-F4-2010-261376, MetaCardis/HEALTH-F4-2012-305312), ERC Advanced Grant Awards to CB (Diatomite: 294823) and PB (CancerBiome: 268985), Spanish Ministry of Science and Innovation grant CGL2011-26848/BOS MicroOcean PANGENOMICS to SGA, JSPS KAKENHI Grant Number 26430184 to HO, FWO, BIO5, Biosphere 2, agne`s b., the Veolia Environment Foundation, Region Bretagne, World Courier, Illumina, Cap L’Orient, the EDF Foundation EDF Diversiterre, FRB, the Prince Albert II de Monaco Foundation, Etienne Bourgois, the Tara schooner and its captain and crew. Tara Oceans would not exist without continuous support from 23 institutes (http://oceans.taraexpeditions.org), Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Gut microbiome variation is associated to Multiple Sclerosis phenotypic subtypes

  • Reynders, Tatjana
  • Devolder, Lindsay
  • Vallès Colomer, Mireia
  • Van Remoortel, Ann
  • Joossens, Marie
  • De Keyser, Jacques
  • Nagels, Guy
  • D'hooghe, Marie Beatrice
  • Raes, Jeroen
Objective: Multiple sclerosis (MS) is a heterogenous, inflammatory disease of the central nervous system. Microbiota alterations in MS versus healthy controls (HC) are observed, but results are inconsistent. We studied diversity, enterotypes, and specific gut microbial taxa variation between MS and HC, and between MS subgroups. Methods: Amplicon sequencing of the 16S ribosomal RNA V4 region (Illumina MiSeq) was used to evaluate alpha and beta diversity, enterotypes, and relative taxa abundances on stool samples. MS subgroups were based on phenotype, disease course modifiers, and treatment status. Results were controlled for recently identified confounders of microbiota composition. Results: Ninety-eight MS patients and 120 HC were included. Microbial richness was lower in interferon-treated (RRMS_I, N = 24) and untreated relapsing-remitting MS during relapse (RRMS_R, N = 4) when compared to benign (BMS, N = 20; Z = -3.07, Pcorr = 0.032 and Z = -2.68, Pcorr = 0.055) and primary progressive MS (PPMS, N = 26; Z = -2.39, Pcorr = 0.062 and Z = -2.26, Pcorr = 0.071). HC (N = 120) and active untreated MS (RRMS_U, N = 24) showed intermediate microbial richness. Enterotypes were associated with clinical subgroups (N = 218, χ2 = 36.10, P = 0.002), with Bacteroides 2 enterotype being more prevalent in RRMS_I. Butyricicoccus abundance was lower in PPMS than in RRMS_U (Z = -3.00, Pcorr = 0.014) and BMS (Z = -2.56, Pcorr = 0.031), lower in RRMS_I than in BMS (Z = -2.50, Pcorr = 0.034) and RRMS_U (Z = -2.91, Pcorr = 0.013), and inversely correlated with self-reported physical symptoms (rho = -0.400, Pcorr = 0.001) and disease severity (rho = -0.223, P = 0.027). Interpretation: These results emphasize the importance of phenotypic subcategorization in MS-microbiome research, possibly explaining previous result heterogeneity, while showing the potential for specific microbiome-based biomarkers for disease activity and severity., MJ is funded by a postdoctoral fellowship from Research Foundation—Flanders. The Raes lab is supported by the VIB, the Rega institute for Medical Research, KU Leuven, the FWO EOS program (30770923), FP7 METACARDIS (305312), H2020 SYSCID (733100), PIBD-SET (668023), and IMMUNAID (779295). This work was funded by an FWO research grant (G038318N) to MD and JR. Financial support for this project in the MS center was provided in 2015, 2016 and 2017, commissioned by the Belgian National MS society with the support of the Fund D.V., managed by the King Baudouin Foundation (2016-C5812060-206012).